经济观察网 东北制药研发投入持续加力，2025年前三季度研发费用达1.04亿元，同比增长95%，重点投 向细胞治疗等创新药管线。控股子公司北京鼎成肽源自主研发的DCTY0801注射液已获批临床试验，并 获美国FDA孤儿药资格认证；同时，TCR-T药物DCTY1102注射液为国内首款进入Ⅰ期临床的靶向 KRAS G12D产品，彰显公司在生物制药领域的技术突破。混改后东北制药经营质效提升，2024年归母 净利润4.1亿元，同比增长14.34%；2025年前三季度扣非净利润同比增长27.54%，显示出较强的盈利韧 性和创新转型成效。公司原料药厂区在2月上中旬通过7家国内外客户审计，涉及维生素C等5个核心产 品，通过率100%，进一步巩固了国际市场信任度。 股票近期走势近期东北制药股价呈现震荡走势。截至2026年2月26日收盘，股价报5.20元，当日跌幅 0.38%，近三个交易日（2月24日至26日）区间涨幅1.36%。资金流向显示，2月26日主力净流入787万 元，散户资金呈净流出状态。技术面显示，股价处于20日压力位5.5元与支撑位5.06元之间，MACD指标 偏弱，短期需关注突破情况。 以上内容基于公开资料整理 ...

Mesoblast (NasdaqGS:MESO) H1 2026 Earnings call February 26, 2026 05:00 PM ET Company ParticipantsJames O'Brien - CFOMarcelo Santoro - Chief Commercial OfficerPaul Hughes - Head of Corporate Finance and Investor RelationsSilviu Itescu - CFO and Managing DirectorConference Call ParticipantsEdward Tenthoff - Managing Director and Senior Research AnalystMadeleine Williams - Equity Research AnalystMichael Okunewitch - Biotechnology Senior Research AnalystOlivia Brayer - Director and Senior Biotech AnalystOperat ...

Core Viewpoint - Haitong International reports that the main business revenue and profit of CSPC Pharmaceutical Group (01093) have bottomed out, with expectations to return to an upward cycle by 2026 and benefit from the launch of innovative oncology and metabolic products starting in 2027 [1] Group 1: Revenue and Profit Outlook - The potential milestone revenue for CSPC Pharmaceutical Group is estimated at $5.8 billion (approximately RMB 40.6 billion), which is expected to gradually enhance the company's profits over the next 3-5 years [1] - The firm believes that upfront payments and milestone revenues will provide sustainable recurring income for the company, leading to an upward revision of the revenue forecast for authorized products post-2027 [1] Group 2: R&D and Collaboration - CSPC Pharmaceutical Group has achieved seven external collaboration deals in the past two years, with total upfront payments of $1.71 billion and potential milestone revenues exceeding $30 billion [2] - The company has partnered with AstraZeneca three times, highlighting its R&D platform's global influence and value [2] - The firm is optimistic about CSPC's ability to generate regular income through milestone sales and net revenue sharing throughout the drug lifecycle [2] Group 3: Pipeline and Technology - CSPC's small nucleic acid platform has a broad layout, targeting popular liver delivery points such as PCSK9, AGT, and ANGPTL3, and is ahead of domestic peers in development [3] - The company has applied for patents related to lipid delivery and specific siRNA treatments, indicating potential advancements in neurological and ocular delivery technologies [3] - The SYS6010 (EGFR-ADC) has accumulated clinical data from over a thousand patients, showing potential for best-in-class efficacy and safety [4] Group 4: Clinical Developments - The company has initiated a Phase III clinical trial for SYS6010 in China for first-line treatment of non-small cell lung cancer (NSCLC) and plans to advance global Phase III trials [4] - CSPC's in vivo CAR-T product, SYS6055, has received clinical approval in China, representing the first in vivo CAR-T product approved domestically, with potential advantages in cost and accessibility [4] Group 5: Financial Projections - The firm has adjusted revenue forecasts for FY25, FY26, and FY27 to RMB 26.7 billion, 28.9 billion, and 30.6 billion respectively, reflecting changes in the recognition of upfront payments [5] - The net profit forecasts for FY25, FY26, and FY27 have been revised to RMB 4.4 billion, 4.6 billion, and 5.3 billion respectively [6]

智通财经APP获悉，海通国际发布研报称，石药集团(01093)的主营业务收入、利润已经触底，2026年有 望回到上升周期，2027年开始受益于肿瘤和代谢创新产品放量，成药收入有望提速。石药集团当前潜在 临床里程碑收入达58亿美元（约人民币406亿元），有望在未来3-5年陆续增厚公司利润。该行认为首付 款和里程碑收入将为公司带来可持续的经常性收益，并上调了2027年后的授权收入预测。该行使用现金 流折现（DCF）模型及FY27-FY35的现金流进行估值。基于WACC 7.9%，永续增长率2.5%（均不 变），对应目标价13.07港元，并维持"优于大市"评级。 海通国际主要观点如下： 研发能力多次获得认可，该行看好常态化里程碑收入夯实公司基本面 近两年来石药集团实现7笔对外合作交易，涉及首付款总额17.1亿美元，潜在里程碑总额超300亿美元。 公司与全球顶尖药企阿斯利康三度达成合作，彰显石药集团研发平台在全球范围的影响力与价值。该行 认为，加总近60亿美元的潜在研发里程碑将会在未来3-5年陆续增厚石药集团的利润，成为公司常态化 收入的重要组成部分。该行看好石药集团可以持续以销售里程碑和销售净额分成的方式在整个药品 ...

研究报告 Research Report 25 Feb 2026 石药集团 CSPC Pharmaceutical Group (1093 HK) 跨国药企多次认可，创新转型成果凸显，平台价值值得期待 Multiple Recognitions from MNCs, Clear Progress in Innovation Transformation, Platform Value Highly Anticipated [Table_yemei 观点聚焦 1] Investment Focus [Table_Info] 维持优于大市 Maintain OUTPERFORM 评级 优于大市 OUTPERFORM 现价 HK$10.06 目标价 HK$13.07 HTI ESG 3.0-2.5-3.5 E-S-G: 0-5, (Please refer to the Appendix for ESG comments) 市值 HK$115.92bn / US$14.82bn 日交易额 (3 个月均值) US$140.76mn 发行股票数目 11,522mn 自由流通股 (%) 68% 1 年股价最高最低值 HK ...

研究报告 Research Report 25 Feb 2026 石药集团 CSPC Pharmaceutical Group (1093 HK) 跨国药企多次认可，创新转型成果凸显，平台价值值得期待 Multiple Recognitions from MNCs, Clear Progress in Innovation Transformation, Platform Value Highly Anticipated [Table_yemei 观点聚焦 1] Investment Focus [Table_Info] 维持优于大市 Maintain OUTPERFORM 评级 优于大市 OUTPERFORM 现价 HK$10.06 目标价 HK$13.07 HTI ESG 3.0-2.5-3.5 E-S-G: 0-5, (Please refer to the Appendix for ESG comments) 市值 HK$115.92bn / US$14.82bn 日交易额 (3 个月均值) US$140.76mn 发行股票数目 11,522mn 自由流通股 (%) 68% 1 年股价最高最低值 HK ...

在2025年12月举行的美国血液学会（ASH）年会上，Anitocabtagene autoleucel（anito-cel）在重度预处 理的R/R MM患者中展现出令人振奋的疗效：客观缓解率（ORR）高达96%，完全缓解（CR）或严格完 全缓解（sCR）率达到74%，且缓解持久性良好，安全性可控。这项研究结果不仅为R/R MM患者带来 了新的治疗选择，也进一步巩固了BCMA CAR T疗法在晚期骨髓瘤治疗中的核心地位。 21世纪经济报道记者季媛媛 2月23日，吉利德科学宣布与其长期合作伙伴Arcellx达成最终协议，将以每股115美元现金、总股权价值 约78亿美元的价格收购后者。消息一出，Arcellx盘前股价应声暴涨近80%。 这一收购背后被认为是吉利德旗下Kite Pharma在细胞治疗领域布下的一枚重子。根据协议条款，吉利 德将获得Arcellx的全部控股权，但故事并未结束。Arcellx的股东未来还有机会获得每股5美元的或有价 值权（CVR），而触发条件是核心资产anito-cel在上市后至2029年底，全球累计净销售额达到至少60亿 美元 。 这一"对赌"条款显示了吉利德对anito-cel成为重 ...

Group 1 - The core viewpoint of the news is that Yiqiao Shenzhou (301047) is participating in the 15th Cell Biology Industry Conference, which focuses on cell therapy and regenerative medicine, scheduled for March 5-6, 2026, in Chengdu [1] - The number of shareholders in Yiqiao Shenzhou increased by 2.44% as of February 9, 2026, indicating a change in investor interest [1] Group 2 - Over the past 7 days (February 6 to 11, 2026), Yiqiao Shenzhou's stock price fluctuated within a range of 0.34%, with a high of 74.77 yuan and a low of 73.14 yuan, showing a volatile trend [2] - On February 11, 2026, there was a net outflow of 1.1075 million yuan in main funds, while retail investor activity remained high [2] Group 3 - As of February 12, 2026, institutions set a comprehensive target price for Yiqiao Shenzhou at 78.00 yuan, indicating limited upside potential compared to the latest stock price [3] - The forecast for net profit in 2025 is expected to grow by 18.10%, while revenue for 2026 is projected to increase by 9.06% [3] - Market sentiment is neutral, and the frequency of institutional research is relatively low [3]

Core Insights - The cell therapy market is experiencing rapid growth, with an average annual growth rate exceeding 50%, and is expected to reach a market size of 58.4 billion yuan by 2030 [1] - The implementation of the new regulations for biomedical technology clinical research and application, effective from May 1, 2026, is seen as a foundational law for the industry, promoting a shift towards a comprehensive health management approach [1] Group 1: Company Strategy - Health Road has entered the cell therapy sector through a strategic partnership with He Yuan Bio, indicating its intent to build a comprehensive health service ecosystem [1][2] - The company adopts a light-asset model, focusing on regional agency as a practical approach to accelerate its growth in the cell therapy market [2] - Health Road's collaboration with He Yuan Bio, a company with a robust integrated platform in cell and gene therapy, enhances its industrial capabilities and technological reserves [2] Group 2: Market Positioning - Health Road has established a vast network with 211.8 million registered users and 905,000 registered doctors, allowing it to leverage its existing resources for rapid business expansion [2][4] - The company is focusing on three core areas: cell storage, cell preparation, and exosome preparation, aligning with its comprehensive health service system [2] - The cell storage and preparation business typically has high gross margins and prepayment characteristics, which will further optimize the company's revenue structure and provide stable cash flow [3] Group 3: Competitive Advantage - Health Road's ecosystem enables it to quickly form multi-dimensional synergies, enhancing customer loyalty and service value through its network of over 11,000 medical institutions [4] - The company can introduce innovative product combinations to its vast user base, maximizing user lifecycle value [4] - By leveraging existing resources, Health Road can achieve rapid expansion without the need to build clinical channels and user trust from scratch [4]

Core Viewpoint - AstraZeneca plans to invest over 100 billion RMB in China by 2030 to expand its pharmaceutical production and R&D capabilities, leveraging China's scientific innovation and advanced manufacturing [2] Group 1: Investment Plans - The investment will enhance AstraZeneca's capabilities in cell therapy and radiolabeled drugs, contributing to a diverse product pipeline for cancer, blood diseases, and autoimmune diseases [3] - This investment follows a previous commitment of up to $2.5 billion to establish a strategic R&D center in Beijing, marking AstraZeneca's sixth global and second Chinese R&D center [2] Group 2: R&D and Innovation - As of January 2023, AstraZeneca has invested over $1.8 billion in China and plans to launch 20 global innovative drugs by the end of 2030 [3] - The company currently has over 200 projects in its Chinese R&D pipeline, with 10-15 new projects added annually [3] Group 3: Strategic Importance - AstraZeneca's CEO emphasized that this investment marks a new chapter in the company's development in China, recognizing the country's role in scientific innovation and global public health [2]